Milwaukee-based Estrigenix Therapeutics, a biotechnology company developing selective estrogen receptor-beta (ERβ) therapeutics, has announced the first closing of a USD 2 million Series Seed financing to advance its ERβ platform across women's health and neurodegenerative disease indications. Monies raised will fund lead optimization and completion of a translational preclinical package ahead of IND-enabling studies.
The round was led by Talents Fund I, with no additional co-investors named in the announcement. It follows a period of non-dilutive support for the company, including an earlier National Institute on Aging SBIR Phase I grant and a Wisconsin Economic Development Corporation matching award, as well as angel investment through regional networks. The Series Seed financing represents Estrigenix's first institutional equity raise and arrives roughly three weeks after the company signed an exclusive worldwide license covering its ERβ compound portfolio with the University of Wisconsin–Milwaukee Research Foundation, Inc. (UWMRF), Marquette University, and CU Ventures, Inc. Chief Executive Officer Victoria Zellmer said the financing allows the company to advance a differentiated platform toward clinical development while expanding the range of diseases it could address.
Estrigenix's platform is built around non-steroidal small molecules designed to selectively activate ERβ while sparing ERα, the receptor subtype associated with proliferative effects in the uterus and breast that have limited traditional hormone therapy. ERβ is broadly expressed in brain regions involved in memory and emotional regulation, providing a rationale for pursuing both menopausal symptoms and neurodegenerative disease through what the company describes as a shared biological mechanism. No ERβ-selective agonist has yet reached approval, making receptor selectivity the central technical challenge the platform is intended to address.
The company's most advanced compound, EGX358, is in preclinical development for menopausal vasomotor symptoms and for memory deficits associated with Alzheimer's disease. In ovariectomized mouse models, oral EGX358 moderated induced hot flashes and improved memory to an extent comparable with estradiol, without effects on uterine weight, anxiety, depression or body weight—findings the company points to as a safety differentiator from conventional estrogen-based treatments. Estrigenix said it has attracted interest from multiple pharmaceutical companies regarding its lead candidate, though no partnership has been announced. Beyond EGX358, the licensed portfolio includes additional ERβ small molecules earmarked for lead optimization, though none has been named publicly.